BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 22634534)

  • 1. Biological markers of cisplatin resistance in advanced testicular germ cell tumours.
    García-Velasco A; Durán I; García E; Tarón M; Ballestín C; Castellanos D; Cortés-Funés H; Paz-Ares L
    Clin Transl Oncol; 2012 Jun; 14(6):452-7. PubMed ID: 22634534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 and MDM2 expression in primary and metastatic testicular germ cell tumors: Association with clinical outcome.
    Lobo J; Alzamora MA; Guimarães R; Cantante M; Lopes P; Braga I; Maurício J; Jerónimo C; Henrique R
    Andrology; 2020 Sep; 8(5):1233-1242. PubMed ID: 32384200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased levels of XPA might be the basis of cisplatin resistance in germ cell tumours.
    Cierna Z; Miskovska V; Roska J; Jurkovicova D; Pulzova LB; Sestakova Z; Hurbanova L; Machalekova K; Chovanec M; Rejlekova K; Svetlovska D; Kalavska K; Kajo K; Babal P; Mardiak J; Ward TA; Mego M; Chovanec M
    BMC Cancer; 2020 Jan; 20(1):17. PubMed ID: 31906898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of DNA repair machinery and p53 in the testicular germ cell cancer: a review.
    Romano FJ; Rossetti S; Conteduca V; Schepisi G; Cavaliere C; Di Franco R; La Mantia E; Castaldo L; Nocerino F; Ametrano G; Cappuccio F; Malzone G; Montanari M; Vanacore D; Quagliariello V; Piscitelli R; Pepe MF; Berretta M; D'Aniello C; Perdonà S; Muto P; Botti G; Ciliberto G; Veneziani BM; De Falco F; Maiolino P; Caraglia M; Montella M; De Giorgi U; Facchini G
    Oncotarget; 2016 Dec; 7(51):85641-85649. PubMed ID: 27821802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relative activity of cisplatin, oxaliplatin and satraplatin in testicular germ cell tumour sensitive and resistant cell lines.
    Perry J; Powles T; Shamash J; Veerupillai A; McGrowder E; Noel E; Lu YJ; Oliver T; Joel S
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):925-33. PubMed ID: 19263053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell Tumors.
    Bagrodia A; Lee BH; Lee W; Cha EK; Sfakianos JP; Iyer G; Pietzak EJ; Gao SP; Zabor EC; Ostrovnaya I; Kaffenberger SD; Syed A; Arcila ME; Chaganti RS; Kundra R; Eng J; Hreiki J; Vacic V; Arora K; Oschwald DM; Berger MF; Bajorin DF; Bains MS; Schultz N; Reuter VE; Sheinfeld J; Bosl GJ; Al-Ahmadie HA; Solit DB; Feldman DR
    J Clin Oncol; 2016 Nov; 34(33):4000-4007. PubMed ID: 27646943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic potential of Mdm2 inhibition in malignant germ cell tumours.
    Bauer S; Mühlenberg T; Leahy M; Hoiczyk M; Gauler T; Schuler M; Looijenga L
    Eur Urol; 2010 Apr; 57(4):679-87. PubMed ID: 19560254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apoptosis regulation and spontaneous apoptosis index of testicular germ cell tumors are associated with differentiation and resistance to systemic treatment.
    Mandoky L; Szende B; Géczi L; Bodrogi I; Kásler M; Bak M
    Anticancer Res; 2008; 28(3A):1641-9. PubMed ID: 18630521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Enigmatic Role of TP53 in Germ Cell Tumours: Are We Missing Something?
    Ottaviano M; Giunta EF; Rescigno P; Pereira Mestre R; Marandino L; Tortora M; Riccio V; Parola S; Casula M; Paliogiannis P; Cossu A; Vogl UM; Bosso D; Rosanova M; Mazzola B; Daniele B; Palmieri G; Palmieri G
    Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P53, bcl-2 and bax immunoreactivity as predictors of response and outcome after chemotherapy for metastatic germ cell testicular tumours.
    Baltaci S; Orhan D; Türkölmez K; Yesilli C; Bedük Y; Tulunay O
    BJU Int; 2001 May; 87(7):661-6. PubMed ID: 11350408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of 7 immunohistochemical markers in male germ cell tumors demonstrates the prognostic significance of p53 and MIB-1.
    Pectasides D; Papaxoinis G; Nikolaou M; Valavanis C; Aravantinos G; Fountzilas G; Tamvakis N; Pectasides E; Lekka I; Arapantoni-Dadioti P; Zizi A; Ghiconti I; Economopoulos T
    Anticancer Res; 2009 Feb; 29(2):737-44. PubMed ID: 19331230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of N-cadherin in proliferation, migration, and invasion of germ cell tumours.
    Bremmer F; Schallenberg S; Jarry H; Küffer S; Kaulfuss S; Burfeind P; Strauß A; Thelen P; Radzun HJ; Ströbel P; Honecker F; Behnes CL
    Oncotarget; 2015 Oct; 6(32):33426-37. PubMed ID: 26451610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of
    Timmerman DM; Eleveld TF; Gillis AJM; Friedrichs CC; Hillenius S; Remmers TL; Sriram S; Looijenga LHJ
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic evolution and chemoresistance in germ-cell tumours.
    Taylor-Weiner A; Zack T; O'Donnell E; Guerriero JL; Bernard B; Reddy A; Han GC; AlDubayan S; Amin-Mansour A; Schumacher SE; Litchfield K; Turnbull C; Gabriel S; Beroukhim R; Getz G; Carter SL; Hirsch MS; Letai A; Sweeney C; Van Allen EM
    Nature; 2016 Nov; 540(7631):114-118. PubMed ID: 27905446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
    Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S
    Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting of Deregulated Wnt/β-Catenin Signaling by PRI-724 and LGK974 Inhibitors in Germ Cell Tumor Cell Lines.
    Schmidtova S; Kalavska K; Liskova V; Plava J; Miklikova S; Kucerova L; Matuskova M; Rojikova L; Cierna Z; Rogozea A; Konig H; Albany C; Mego M; Chovanec M
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33923996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of refractory germ-cell tumours with single-agent cabazitaxel: a German Testicular Cancer Study Group case series.
    Oing C; Hentrich M; Lorch A; Gläser D; Rumpold H; Ochsenreither S; Richter S; Dieing A; Zschäbitz S; Pereira RR; Bokemeyer C; Seidel C
    J Cancer Res Clin Oncol; 2020 Feb; 146(2):449-455. PubMed ID: 31838576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IGF1R signalling in testicular germ cell tumour cells impacts on cell survival and acquired cisplatin resistance.
    Selfe J; Goddard NC; McIntyre A; Taylor KR; Renshaw J; Popov SD; Thway K; Summersgill B; Huddart RA; Gilbert DC; Shipley JM
    J Pathol; 2018 Feb; 244(2):242-253. PubMed ID: 29160922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of Oct-3/4 expression in embryonal carcinoma cells is associated with induction of cisplatin resistance.
    Mueller T; Mueller LP; Luetzkendorf J; Voigt W; Simon H; Schmoll HJ
    Tumour Biol; 2006; 27(2):71-83. PubMed ID: 16557044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of P53 and MDM2 in treatment response of human germ cell tumors.
    Kersemaekers AM; Mayer F; Molier M; van Weeren PC; Oosterhuis JW; Bokemeyer C; Looijenga LH
    J Clin Oncol; 2002 Mar; 20(6):1551-61. PubMed ID: 11896104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.